Ciftci 2012.

Methods	Single‐centre, randomised study
Participants	Patients with lung cancer
Interventions	Intervention: warfarin in addition to standard anticancer treatment. Warfarin orally for 6 months starting on day 1 of chemotherapy at a dose of 5 mg/day to achieve a target international normalised ratio of 1.5–2.5 Control: standard anticancer treatment
Outcomes	No clear distinction between primary and secondary outcomes. Outcomes reported in the abstract: overall median survival, response rates (complete and partial), bleeding
Notes	Reason to be listed as awaiting classification: no outcome data extractable, trial not yet published as full article.